Biophytis S.A. (ALBPS) is a Biotechnology company in the Healthcare sector, listed on Euronext Paris. This page provides the complete earnings calendar, dividend schedule, and financial data for Biophytis S.A. in 2026. The next earnings report is expected on September 11, 2026.
Next earnings date
11 Sep 2026
In 21 days
EPS estimate
-0.29
Revenue estimate
0
Past earnings
No dividend history available.
Biophytis S.A. is a clinical-stage biotechnology company dedicated to creating therapies designed to mitigate age-related degenerative processes and enhance functional well-being for patients. The company's scientific approach centers on identifying and activating critical biological resilience pathways, aiming to protect against and counteract the diverse biological and environmental stressors that contribute to age-related diseases. Its primary drug candidate, Sarconeos (BIO101), is an orally administered small molecule currently in development for neuromuscular conditions such as sarcopenia and Duchenne muscular dystrophy (DMD). Sarconeos is also undergoing a Phase 2/3 clinical study investigating its potential to treat severe respiratory failure in individuals with COVID-19. Furthermore, Biophytis is advancing Macuneos (BIO201), another oral small molecule, for the management of retinal disorders including dry age-related macular degeneration (AMD) and Stargardt disease. The firm maintains a collaborative agreement with AFM-Telethon specifically for the development of Sarconeos (BIO101) in DMD. Founded in 2006, Biophytis S.A. is headquartered in Paris, France.
Biophytis S.A. (ALBPS) is scheduled to report earnings on September 11, 2026.
Biophytis S.A. (ALBPS) last reported earnings on July 11, 2025.
Biophytis S.A. (ALBPS) is listed on Euronext Paris.
We use cookies to make our website work and improve your experience. With your consent, we also use cookies for analytics and advertising.